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1055-l 52 Matrix-Immobilized Fibroblast Growth Factor Genes 
Promoted Angiogenesis in a Porcine Model of Chronic 
Myocardial lschemia 
Kun-Lun He, Eva M. Becker, Geng-Hua Yi, Satoshi Mohri, Anguo Gu, Ge-Ping Zhang, 
Myung J. Lee, Jie Wang, Barbara A. Sosnowski, Glenn F. Pierce, John Doukas. Daniel 
Burkhoff, Circulatory of Physiology and Cardiology, Columbia University, New York, NY 
Background: Direct injections of genes encoding fibroblast growth factor (FGF) have 
been tested for inducing angiogenesis in ischemic myocardium, but retention of the 
genes at the injection site may limit its effectiveness. Previous studies demonstrated that 
matrix-immobilized FGF gene therapy enhances angiogenesis in skeletal muscle 
wounds. We therefore tested the effects of matrix-immobilized FGF gene therapy on 
regional angiogenests in a porcine model of chronic myocardial lschemia model. 
Methods: 16 pigs underwent ameroid placement around the left circumflex coronary 
artery (LCx). At 4 weeks, animals. randomly received 15 intra-myocardium injections 
(0.1 ml/each injection, 5x10” viral particles/ml) of matrix-immobilized human adenovirus 
vectors encoding either FGFP (n=5) or FGFG (n=5) genes or a control vector without pro- 
moter or transgene insert (1x6) in LCx territory. Myocardial perfusion assessed by color 
microspheres at rest and during vasdilatory stress (adenosine) was performed before 
and 4 weeks after treatment. BrdU was injected subcutaneously during follow-up to mark 
dividing cells. 
Results: Resting blood flow showed a small amount of ischemia in the LCX territory 
which was not influenced by gene therapy. During adenosine stress, however, myocar- 
dial blood flow (expressed as a percent flow in the normal, nonischemic zone) was 
greater in the LCx territory in treated animals compared to controls (epicardial: 
77.0*5.1% vs 68.6+3.6%. ~~0.05; endocardial: 75.6+2.6% vs 67.5t4.7%. ~0.05) 4 
weeks after genes treatment. These benefits were accompanied by histologic evidence 
of increased BrdU staining using a semi-quantitative score (epicardial: 3.2i0.6 vs 
2.1+0.8; mid-myocardial: 3.1+0.9 vs 1 .Q*l .O; endocardial: 2.7il .O vs 1.5*0.8, ~0.05 for 
each comparison) and overall vascular growth score (epicardial: 2.4*0.6 vs 1.6kO.6; mid- 
myocardial: 2.4eO.6 vs 1.5*0.5; endocardial: 2.2kO.6 vs 1.5eO.5, ~~0.05 for each com- 
parison). 
Conclusions: Matrix immobilized FGF genes treatment results in significant increase in 
myocardial perfusion and vascularity in a porcine model of chronic ischemia. The 
approach may enhance the effectiveness of gene therapy. 
1055-l 53 Detection of Unique Factors Involved in Coronary 
Collateral Growth: Analysis of the Cardiac Interstitial 
Subproteome 
Nicole L. Lohr, Dorothee Weihrauch, David C. Warltier, William M. Chilian, Medical 
College of Wisconsin, Milwaukee, WI, Louisiana State University Health Science Center, 
New Orleans, LA 
Background: Angiogenic and arteriogenic gene therapy in the heart has yet to be real- 
ized, despite the fact that a well developed coronary collateral vasculature has tremen- 
dous therapeutic benefit. One complication of past therapeutic angiogenic approaches is 
that a single factor was used, and perhaps this is the reason for failure; namely,other crit- 
ical factors were overlooked. Accordingly, our goal was to detect unique factors involved 
in coronary collateralization. Methods: We utilized a canine model of collateral develop- 
ment (repetitive ischamia [RI]: one 2 min occlusion/hou$, E/day, for 21 days after which 
collateral flow equals that in the normal zone) in which we collected myocardial interstitial 
fluid (MIF) using an intramyocardial catheter. Since angiogenesis relies on the interaction 
of proteins in the extracellular environment, our focus was to analyze the MIF for a sub- 
proteome of blood borne and/or secreted factors associated with collateral growth via 
comparison between RI and Sham groups (without RI). Briefly, 30~1 of MIF was electro- 
phoresed (2-D; pH gradient, 4.0-7.0; 18% polyaciylamide gel for optimal separation of 
proteins under 25 kDa). Results: Spot analysis revealed approximately 72 proteins 
present in MIF of the experimental group but not in MIF of the sham group 7 days after 
initiation of RI. We selected 1 distinct protein and identified it using trypsin digestion in 
conjunction with MALDI-TOF mass spectroscopy. The protein, with an approximate 
molecular weight of 20 kDa and a pl of 5.5, exhibits significant homology to the human Fc 
gamma receptor I, which is expressed by macrophages and neutrophlls. Presence of this 
protein implies inflammatory cell recruitment to the ischemic zone. Perhaps future thera- 
peutic angiogenic approaches should consider amplification of such endogenous mecha- 
nisms that would stimulate monocyte and polymorphonucleocyte migration to facilitate 
collateral vessel formation. Conclusion: These data demonstrate the utility of identifying 
a subproteome of interstitial factors within the normal sequelae of ischemic heart disease 
and compensatory collateral growth. 
1055-154 Arteriogenesis Is Reduced in CD44 Knockout Mice 
Niels van Raven, Imo Hoefer, Michiel Voskuil, Ronald van der Neut, Christoph Bode, Ivo 
R. Buschmann. Steven Pals. Jan J. Piek. Academic Medical Center, Universitv of 
Amsterdam, Amsterdam, The Netherlands, University of Freiburg, Freiburg, Germany 
Introduction and hypothesis: The CD44 receptor mediates the transformation of inactwe 
TGF-R into active TGF-0. Moreover, CD44 mediates the presentation of bFGF by mac- 
rophages to the FGF receptor-l on adjacent cells. Since both active TGF-B as well as b- 
FGF have profound pro-arteriogenic effects we hypothesized that CD44 mediates the 
arteriogenic response upon arterial occlusion. We tested this hypothesis in a model of 
femoral artery ligation in CD44 -/- mice. Methods: The right femoral artery of CD44 
knockout mice as well as their matching controls (C57Ibl6) were occluded with a double 
ligation, just distal from the ligamentum inguinalis. Seven days after ligation, Immunohis- 
tochemistly was performed to detect CD44 expression. In addition, the distal abdominal 
aorta was cannulated and both hindlimbs were perfused with a physiological buffer solu- 
tion at 4 different pressure levels (ranging from 70 to 100 mmHg). At each pressure level 
a differently coloured microsphere was infused. Maximal vasodilation was achieved 
using adenosine (lmg/kg/min). Microspheres were quantified via FACS-analysis and 
flow was calculated for each muscle sample. Data are expressed as percentage of nor- 
mal maximal perfusion. Results: In control mice a strongly increased staining for CD44 
was observed in proliferating collateral arteries as identified by Kl67. 7 days after femoral 
artery ligation C57/bl6 control mice showed a 55% * 7% restoratlon of normal flow. For 
CD44 -I- mice a 23% * 4% flow restoration was observed (p < 0.01). Conclusion: This 
study, for the first time has shown the role of CD44 during arteriogenesis. During natural 
arteriogenesis the expression of CD44 is upregulated in growing collateral arteries. 
Moreover, the absence of this receptor reduces significantly the natural restoration of 
flow upon femoral arlely occlusion. 
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1056-118 Does the -514T Gene Promoter Variant of Hepatic 
Lipase Predict Increased High-Density Lipoprotein 
Levels and Reduced Risk of Angiographic Coronary 
Artery Disease? 
Brvant M. Whiting, Jeffrey L. Anderson, Coly A. King, Jason McKinney, Joseph B. 
Muhlestein, Kaisorn Chaichana, Tami L. Bair, Sandra P. Reyna, Benjamin D. Home, 
John F. Carlquist. LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, 
UT 
Background: Hepatic lipase (HL) is a key enzyme in lipoprotein metabolism and reverse 
cholesterol transport. HL activity increases the density and atherogenicity of LDL parti- 
cles and decreases HDL. The variant T allele of a common polymorphism in the pro- 
moter region of the HL gene (C-514T) is associated with decreased HL activity. Carriers 
of the variant -514T allele might be at lower risk for coronary artery disease (CAD), but 
clinical studies are limited and conflicting. Our objective was to evaluate C-514T as a 
protective factor for CAD in a large, prospectively ascertained population, and confirm its 
reported effect on plasma lipids. 
Methods: To assess the risk of the C-514T HL polymorphism for CAD (270% stenosis), 
we prospectwely genotyped 3,868 consenting patients undergoing diagnostic coronary 
angiography. Genotyping employed PCR amplification of the promoter region and single 
probe hybridization with melting curve analysis using the SNP Odyssey Analyzer (Idaho 
Technology). 
Results: Overall genotype frequency was: CC, 58.5%; CT, 36 0%; TT, 5.5%. Plasma 
LDL did not differ by genotype: CC, 112.4 mg/dL; CT, 110.9 mg/dL; TT. 106.4 mg/dL 
(p=NS). However, the lT genotype was associated with sigmficantly higher plasma HDL: 
CC, 38.2 mg/dL; CT, 39.8 mg/dL; TT, 43.2 mg/dL (p<O.OOl). Allele frequencies were sim- 
ilar among patients with significant CAD (n=2.696) and angiographically normal controls 
(n=l,i72): C allele, 0.76 vs 0.77, respectively; T allele, 0.24 vs 0.23, respectively. Sims- 
larly, no difference in diagnosis of CAD was observed by genotype: CC, 69%; CT, 71%; 
TT 68% (p=NS). 
Conclusions: This large, prospective study confirmed a beneficial effect of the HL C-514T 
polymorphism on plasma lipids (increased HDL) but failed to find a postulated protective 
association between the HL C-514T polymorphism and the presence of angiograph!cally 
defined CAD. The reason for the discrepancy between Intermediate phenotype (lipids) 
and clinical disease (CAD prevalence) is uncertain, but it suggests the presence of 
genetically-linked effect modifiers that deserve further exploration. 
1056-119 Effects of Fenofibrate on Transcription of DNA Variants 
at 5 Untranslated Region of Human Apolipoprotein A-l 
Gene 
Akin Matsunaqa, Hideya Nimura, Kazuo Owaki. Kazue Yonemura, Keljiro Saku, School 
of Medicine, Fukuoka University, Fukuoka. Japan 
Previously, we demonstrated that point mutations at nucleotide position -27 of the puta- 
tive TATA box signal sequence and G to A substitution at position -75 of apolipoprotein 
(apo) A-l gene, and were accompanied with decrease in expression of apoA-I (Arterio- 
scler Thromb Vast Biol 19348.355, 1999). Here we report on the effects of hypolipi- 
demic drug, fenofibrate on the variant of apoA-I promoter elements. We cloned the 5 
region of the apoA-I gene (-333 to +119 bp) with wild type (-27A/-75G), and variant hap- 
lotypes (-27Ai-75A. -27C/-75G, and -27C/-75A ) into a pGL3-luciferase reporter gene 
basic vector, and transfected the constructed vectors into HepG2 cells. The plasmid, 
pSV-beta-galactosidase control vector was included in each transfection to normalize the 
transfection efficiency. The transcriptional levels of variant promoters -27AJ-75A, -27Cl- 
75G, and -27C/-75A, assessed by luciferase assay, were 39, 42 and 24% compared 
with those of wild type (-27Ai-75G). Fenofibrate (0.200mM) increased the transcriptional 
levels of wild type and mutant promoter elements in a dose-dependent manner. Relative 
transcriptional levels of wild type (-27Ai-75G), -27Al-75A, -27C/-75G, and -27Ci-75A in 
HepG2 cells treated with fenofibrate (200mM) increased 186,135, 141, and 113%, 
respectively. These results suggest that fenofibrate Increase the transcription of the vari- 
ant apoA-I promoter elements, -27 TATA box and -75 G/A substitutions. 
